Work

Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa

Year: 2024

Type: article

Abstract: Risankizumab-rzaa (RZA) is a fully human immunoglobulin G monoclonal antibody (Mab) which has fewer immunogenic concerns compared with chimeric Mabs. The pivotal trials of RZA found no significant differences in infusion reactions between drug and placebo. This case illustrates successful transition to subcutaneous RZA following a serious hypersensitivity reaction to intravenous RZA.

Source: ACG Case Reports Journal

DOI: 10.14309/crj.0000000000001546

Authors: David Choi, Benjamin McDonald, David T. Rubin

Institutions: University of Chicago, University of Chicago Medical Center

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceuticals